Poly Medicure has shared an updated investor presentation with the BSE and NSE, making it accessible to stakeholders through the company's official website. The presentation provides comprehensive insights into the company's current operational capabilities and manufacturing infrastructure.

Manufacturing Infrastructure

The updated presentation highlights Poly Medicure's substantial manufacturing footprint across the medical devices sector. The company's operational scale demonstrates its significant presence in the industry.

Investor Communication

The company has ensured transparency by filing the updated presentation with both major stock exchanges and making it readily available to investors and stakeholders through its website. This move reflects the company's commitment to keeping stakeholders informed about its operational capabilities and business scale.

The presentation serves as a comprehensive resource for investors seeking detailed information about Poly Medicure's manufacturing capabilities and production capacity in the medical devices segment.

Poly Medicure Limited has received a clean monitoring report from CRISIL Ratings Limited for its Qualified Institutions Placement (QIP) fund utilization during the quarter ended December 31, 2025. The monitoring agency confirmed no deviation from the stated objects of the issue, with the company successfully deploying Rs 47,431.17 lakh of the total Rs 98,534.37 lakh net proceeds.

QIP Fund Raising Overview

The company raised Rs 99,999.98 lakh through its QIP conducted in August 2024, with key parameters detailed below:

CRISIL Monitoring Report Highlights

CRISIL Ratings Limited, serving as the monitoring agency under SEBI regulations, issued its report dated February 12, 2026, confirming compliance with all regulatory requirements. The monitoring agency found no material deviations from the objects stated in the placement document and verified that all fund utilizations align with the original disclosures.

Quarterly Fund Utilization Breakdown

The company's fund deployment across three primary objectives shows systematic progress:

Major Acquisition Completed

During the quarter, the company completed a significant acquisition through its wholly-owned subsidiary Poly Medicure B.V. The acquisition of Medistream SA Group, consisting of CitiEFFE SRL Italy and its subsidiaries CitiEFFE Inc USA and CitiEFFE De Mexico, was completed for approximately Rs 24,070.56 lakh. Of this amount, Rs 18,070.86 lakh was funded from QIP proceeds while Rs 5,999.70 lakh came from internal accruals.

Unutilized Proceeds Investment

The remaining Rs 51,103.20 lakh of unutilized proceeds have been prudently invested to generate returns:

Regulatory Compliance

The company filed its compliance statement under Regulation 32 of SEBI Listing Regulations on February 13, 2026. Both the Audit Committee and statutory auditors M/s Doogar & Associates provided no adverse comments on the fund utilization pattern. Company Secretary Avinash Chandra and CFO Natesh Vijayvergiya signed the compliance documents, ensuring adherence to all regulatory requirements.